Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19

View Corporate Presentation
COVAXIN Phase 3 Interim Results in India Demonstrates Efficacy of 81%

Innovation in
Eye Therapeutics

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”. And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.
Sign up to receive email alerts with the latest news from Ocugen Subscribe